Skip to main content
Top
Published in: Rheumatology International 7/2010

01-05-2010 | Case Report

Chronic inflammatory demyelinating polyradiculoneuropathy in a boy with systemic lupus erythematosus

Authors: Morel Ayala Zoilo, Benadón Eduardo, Faugier Enrique, Maldonado V. M. del Rocio

Published in: Rheumatology International | Issue 7/2010

Login to get access

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired, autoimmune peripheral neuropathy. Systemic lupus erythematosus (SLE) is a multisystemic, autoimmune disease that can affect the central nervous system in about 40% of patients, with prevalence and incidence unknown in the pediatric population due to lack of multicenter studies. We report the case of a 13-year-old Mexican boy, diagnosed with CIDP at the onset of SLE, beginning with progressive muscle weakness of lower and upper limbs, without affection of the central nervous system. The patient had positive ANA, antiDNAdc, antiBeta2glycoprotein, anti-cardiolipin, ANCA-C and X. He received intravenous immunoglobulin, cyclophosphamide, steroids, and azathioprine and showed clinical improvement. It is important to take into account the presence of peripheral neurological disorders in patients with pediatric SLE, considering CIDP as an uncommon presentation, making the diagnosis important for better treatment and evolution.
Literature
2.
3.
go back to reference Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50:621–637PubMed Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50:621–637PubMed
6.
go back to reference Campello I, Almarcegui C, Velilla J, Hortells JL, Oliveros A (2001) Peripheral neuropathy in systemic lupus erythematosus. Rev Neurol 33(1):27–30PubMed Campello I, Almarcegui C, Velilla J, Hortells JL, Oliveros A (2001) Peripheral neuropathy in systemic lupus erythematosus. Rev Neurol 33(1):27–30PubMed
8.
go back to reference Lijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F et al (2008) Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. The Refractory Peripheral Neuropathy Study Group of Japan. J Neurol Neurosurg Psychiatry 79:1040–1043. doi:10.1136/jnnp.2007.128132 CrossRef Lijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F et al (2008) Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. The Refractory Peripheral Neuropathy Study Group of Japan. J Neurol Neurosurg Psychiatry 79:1040–1043. doi:10.​1136/​jnnp.​2007.​128132 CrossRef
9.
go back to reference San-Juan OD, Castro-Macías JI (2008) Polirradiculoneuropatía crónica inflamatoria desmielinizante. Experiencia de 10 años en un centro mexicano. Rev Neurol 46(11):656–659PubMed San-Juan OD, Castro-Macías JI (2008) Polirradiculoneuropatía crónica inflamatoria desmielinizante. Experiencia de 10 años en un centro mexicano. Rev Neurol 46(11):656–659PubMed
10.
go back to reference Loh WF, Hussain IM, Soffiah A, Lim YN (2000) Neurological manifestations of children with systemic lupus erythematosus. Med J Malays 55:459–463 Loh WF, Hussain IM, Soffiah A, Lim YN (2000) Neurological manifestations of children with systemic lupus erythematosus. Med J Malays 55:459–463
11.
go back to reference Spirin NN, Bulanova VA, Pizova NV, Shilkina NP (2007) Peripheral nervous system lesion syndromes and the mechanisms of their formation in connective tissue diseases. Neurosci Behav Physiol 37(1):1–6. doi:10.1007/s11055-007-0141-1 Spirin NN, Bulanova VA, Pizova NV, Shilkina NP (2007) Peripheral nervous system lesion syndromes and the mechanisms of their formation in connective tissue diseases. Neurosci Behav Physiol 37(1):1–6. doi:10.​1007/​s11055-007-0141-1
12.
go back to reference Servioli L, Pérez C, Consani S, Suárez A, Sehabiaga G, Collazo C, Catala G (2007) Prevalence and characteristics of immunomediated neuropathies in a group of patients with autoimmune diseases. J Clin Neuromuscul Dis 9:285–290CrossRefPubMed Servioli L, Pérez C, Consani S, Suárez A, Sehabiaga G, Collazo C, Catala G (2007) Prevalence and characteristics of immunomediated neuropathies in a group of patients with autoimmune diseases. J Clin Neuromuscul Dis 9:285–290CrossRefPubMed
13.
go back to reference Galeazzi M, Annunziata P, Sebastiani GD et al (2000) Antiganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus. Clinical, serological and HLA class 11 gene associations. J Rheumatol 27:135–141PubMed Galeazzi M, Annunziata P, Sebastiani GD et al (2000) Antiganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus. Clinical, serological and HLA class 11 gene associations. J Rheumatol 27:135–141PubMed
15.
go back to reference Hughes RA, Swan AV, van Doorn PA (2004) Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD003280 Hughes RA, Swan AV, van Doorn PA (2004) Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD003280
16.
go back to reference Gladstone DE, Prestrud AA, Brannagan TH (2005) High-dose cyclophosphamide results in long term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 10:11–16. doi:10.1111/j.1085-9489.2005.10104.x CrossRefPubMed Gladstone DE, Prestrud AA, Brannagan TH (2005) High-dose cyclophosphamide results in long term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 10:11–16. doi:10.​1111/​j.​1085-9489.​2005.​10104.​x CrossRefPubMed
Metadata
Title
Chronic inflammatory demyelinating polyradiculoneuropathy in a boy with systemic lupus erythematosus
Authors
Morel Ayala Zoilo
Benadón Eduardo
Faugier Enrique
Maldonado V. M. del Rocio
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1008-2

Other articles of this Issue 7/2010

Rheumatology International 7/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine